Swiss Semiconductors Stock News

Earnings and Dividend Decisions Put Kuehne + Nagel International in Focus Kuehne + Nagel International (SWX:KNIN) is back on investors’ radar after reporting full year 2025 results that included lower sales, softer earnings and a reduced annual dividend per share. See our latest analysis for Kuehne + Nagel International. The earnings miss and lower dividend appear to have weighed on sentiment, with the share price at CHF172.15 and a 1 year total shareholder return of 14.5% decline, while the...

If you have been wondering whether Roche Holding shares are now offering good value or pricing in a lot of optimism, you are not alone. The stock last closed at CHF 332.40, with a 7 day return of an 8.4% decline, a 30 day return of a 6.7% decline, a 1 year return of 11.7% and a 3 year return of 40.4%. Recent moves in the share price sit against ongoing attention on Roche Holding as a major healthcare group, including continuing focus on its pharmaceuticals and diagnostics businesses and...

Cosmo Pharmaceuticals (SWX:COPN) has kicked off FY 2025 with first half revenue of €51.7 million and a basic EPS loss of €0.13, following FY 2024 second half revenue of €130.6 million with basic EPS of €3.45 and first half 2024 revenue of €136.2 million with basic EPS of €4.42. Over the trailing twelve months in the data, revenue is €182.3 million with basic EPS of €3.68. Investors may focus on how the latest dip into a small loss fits against a period where margins and earnings have...

Why Galderma’s latest results matter for shareholders Galderma Group (SWX:GALD) just reported record full year 2025 figures, with net sales of US$5,207 million and net income of US$613 million, and paired that with fresh 2026 guidance and product milestones. For investors, the combination of earnings, a completed share buyback and detailed growth expectations provides new information about how management is running the business and prioritising capital allocation. See our latest analysis for...

Why the Bichsel decision matters for Galenica shareholders Galenica (SWX:GALE) has launched a consultation process on a planned production closure at its Bichsel subsidiary, a move that could affect up to 170 jobs by the end of 2026. The company plans to support affected employees with financial assistance, career guidance, and potential alternative roles within the wider Galenica network. A final decision is expected after the consultation concludes in mid March 2026. See our latest analysis...

Idorsia (SWX:IDIA) is back on watch for investors after a recent stretch of weak share performance, with the stock showing negative moves over the past week, month and past 3 months. See our latest analysis for Idorsia. At a share price of CHF3.53, Idorsia’s recent share price returns show pressure in the short term, including a 1 day decline of 3.55% and a year to date drop of 13.05%. In contrast, the 1 year total shareholder return of just over 3x and the deeply negative 3 and 5 year total...

Why Zurich Insurance Group (SWX:ZURN) is back on investors’ radar Zurich Insurance Group (SWX:ZURN) has drawn fresh attention after reporting its highest-ever annual profit for 2025, supported by its U.S. Farmers Management Services business and a benign catastrophe year. The board has also proposed lifting the dividend to CHF 30 per share, a 7% increase, subject to shareholder approval, giving investors a fresh data point to reassess the stock. See our latest analysis for Zurich Insurance...

Amrize (SWX:AMRZ) has introduced its new EVERtect™ high-performance concrete range for customers in North America. The portfolio includes multiple specialized mixes tailored for different construction uses across the U.S. and Canada. The launch expands Amrize’s presence in high-spec concrete solutions for both structural and low-carbon applications. For you as an investor, this move highlights how Amrize is positioning its core materials business around more differentiated, higher-spec...

If you are wondering whether ABB's current share price still makes sense after a strong run, this article breaks down what you are really paying for the business today. ABB shares last closed at CHF 67.20, with returns of 46.1% over 1 year and 181.5% over 5 years. The shorter term picture is mixed, with a 4.8% decline over 7 days but a 9.7% gain year to date. Recent headlines have focused on ABB's ongoing position as a major player in electrification and automation, as well as its exposure...

Alcon reports that more than 175 million of its intraocular lenses have been implanted worldwide. The milestone highlights broad adoption of the company’s presbyopia-correcting IOLs across global eye care practices. Alcon plans further intraocular lens launches, subject to regulatory approvals. For investors following Alcon (SWX:ALC), this update comes with the shares trading at CHF63.96 and a value score of 4. The stock shows a 22.3% decline over the past year, while 3-year and 5-year...

On 24 February 2026, Iconovo AB announced it had signed a Letter of Intent with Lonza Group to pursue a long-term collaboration around spray dried formulation capabilities for inhalable biologics, building on their existing work on an obesity project. This potential alliance links Lonza’s CDMO scale with Iconovo’s five-platform inhaler technology targeting biologics and high-value respiratory franchises with global turnover of about US$9.00 billion. We’ll now examine how this focus on spray...

Avolta AG recently completed the cancellation of about 4.9 million treasury shares, reducing its registered share capital to CHF 708,241,695 across 141,648,339 shares, while continuing to expand its food and beverage footprint at key airports in Italy and Canada. This combination of a tighter share base and integrated travel retail and dining growth highlights Avolta’s focus on capital efficiency alongside strengthening its airport partner relationships. Next, we’ll examine how Avolta’s...

Zurich Insurance Group has confirmed the acquisition of UK based insurer Beazley, following completion of an accelerated equity offering to fund the deal. The transaction expands Zurich's presence in international insurance markets and follows investor backing via fresh equity capital. The company, trading as SWX:ZURN, remains in focus as integration plans and capital impacts come into view for shareholders. Zurich Insurance Group, ticker SWX:ZURN, is approaching this deal with a current...

Sandoz Group (SWX:SDZ) has received EU marketing authorization for Ranluspec. The approval expands the company’s biosimilars portfolio into the ophthalmology segment. The decision supports an expected product launch later in 2026 across European markets. For you as an investor, this represents a business development in a high-value area of medicine. Sandoz focuses on biosimilars and generics, and Ranluspec adds another product aimed at chronic eye conditions where long-term treatment is...

dormakaba Holding (SWX:DOKA) moved into focus after its H1 2026 results, reporting sales of CHF 1,362.7 million and net income of CHF 40.5 million, both below the prior half year. See our latest analysis for dormakaba Holding. The H1 2026 earnings release helps explain why the 90 day share price return sits at a decline of 13.01%, even though the 3 year total shareholder return is a gain of 41.09% and recent momentum has weakened despite a 3.60% 1 day share price return to CHF57.5. If this...

Sulzer AG has reported its full-year 2025 results, with sales of CHF 3,555.4 million, net income of CHF 292.8 million, and record EBITDA of CHF 556 million, marking a third consecutive year of margin expansion despite currency and geopolitical pressures. An increased dividend, a higher-margin aftermarket business now contributing 62% of turnover, and record profitability across divisions highlight how Sulzer’s operational excellence and services focus are reshaping its earnings...

Clariant (SWX:CLN) just posted its FY 2025 numbers with first half revenue of CHF 1,981 million and basic EPS of CHF 0.08, setting a cautious tone against a backdrop of trailing 12 month revenue of CHF 3,915 million and a basic EPS loss of CHF 0.23. The company has seen revenue hold in a tight band from CHF 2,070 million in the first half of 2024 to CHF 2,082 million in the second half of 2024, alongside EPS moving from CHF 0.48 to CHF 0.26. This now feeds into a mixed margin picture for...

Adecco Group (SWX:ADEN) has proposed three new nominees for its Board of Directors: Tobias Knechtle, Matthias Rebellius, and Jacques Sanche. Two longstanding board members, Kathleen Taylor and Didier Lamouche, are planned to step down from their roles. The changes represent a significant shift in board composition for one of the world's largest staffing firms. Adecco Group, listed in Switzerland under SWX:ADEN, operates at the center of global staffing, recruitment, and workforce solutions...

OC Oerlikon (SWX:OERL) has drawn fresh attention after reporting a full year 2025 net loss of CHF 19 million, while its board proposed a total dividend of CHF 0.85 per share, including a one time extraordinary payout. See our latest analysis for OC Oerlikon. At a share price of CHF4.23, OC Oerlikon has seen strong short term momentum, with a 30 day share price return of 18.16% and a 90 day share price return of 33.95%, even though the 5 year total shareholder return of 46.83% loss shows a...

If you are wondering whether Novartis shares are still reasonably priced at around their current level, this article walks through what the numbers say about value so you can judge for yourself. With the stock at about US$130.50 and returns of 3.2% over 7 days, 14.3% over 30 days, 20.3% year to date, 38.4% over 1 year, 94.4% over 3 years and 109.0% over 5 years, many investors are asking whether the recent performance already reflects the key positives. Recent coverage around Novartis has...

Holcim AG has released its full-year 2025 results, reporting sales of CHF 15,724 million versus CHF 16,201 million in 2024 and net income of CHF 13.18 billion compared with CHF 2.93 billion, alongside sharply higher basic earnings per share of CHF 23.85. The contrast between lower sales and very large growth in net income and earnings per share suggests significant non-operational or one-off effects that investors will want to unpack on the 2025 earnings call held on 27 February 2026. We’ll...

Julius Bär Gruppe (SWX:BAER) has appointed Winfried Daun as Global Head of Brand & Marketing in a newly created leadership role. The company has introduced new model portfolios for UK financial advisers as part of an expanded UK wealth management approach. Julius Bär Gruppe, a Swiss private banking group, focuses on wealth management services for high net worth and ultra high net worth clients. The new marketing appointment and the UK model portfolios arrive as many wealth managers look to...

Alcon FY 2025 earnings: revenue push with mixed profit signals Alcon (SWX:ALC) has wrapped up FY 2025 with fourth quarter revenue of US$2.7 billion and basic EPS of US$0.44, alongside trailing 12 month revenue of US$10.4 billion and basic EPS of US$1.99 that frame the latest print against a fuller year of performance. The company has seen quarterly revenue move from US$2.5 billion in Q4 2024 to US$2.7 billion in Q4 2025, while basic EPS shifted from US$0.57 to US$0.44 over the same period...

Recently, ABB has seen elevated trading activity in pre-market sessions, supported by ongoing industrial demand and strong spending in robotics and electrification solutions. An interesting angle is that third-party AI-driven models are flagging medium-term growth opportunities for ABB, even as some valuation concerns remain. We’ll now examine how this renewed confidence in robotics and automation demand fits into, and potentially reshapes, ABB’s existing investment narrative. The future of...